This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toropainen, M.
Right arrow Articles by Käyhty, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toropainen, M.
Right arrow Articles by Käyhty, H.

 Previous Article  |  Next Article 

Infection and Immunity, May 2006, p. 2803-2808, Vol. 74, No. 5
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.5.2803-2808.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Protection by Meningococcal Outer Membrane Protein PorA-Specific Antibodies and a Serogroup B Capsular Polysaccharide-Specific Antibody in Complement-Sufficient and C6-Deficient Infant Rats

Maija Toropainen,1* Leena Saarinen,1 Gestur Vidarsson,2,3 and Helena Käyhty1

National Public Health Institute, Department of Vaccines, Helsinki, Finland,1 Immunotherapy Laboratory, Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands,2 Laboratory of Vaccine Research, The Netherlands Vaccine Institute, Bilthoven, The Netherlands3

Received 4 November 2005/ Returned for modification 9 December 2005/ Accepted 9 February 2006

The relative contributions of antibody-induced complement-mediated bacterial lysis and antibody/complement-mediated phagocytosis to host immunity against meningococcal infections are currently unclear. Further, the in vivo effector functions of antibodies may vary depending on their specificity and Fc heavy-chain isotype. In this study, a mouse immunoglobulin G2a (mIgG2a) monoclonal antibody (MN12H2) to meningococcal outer membrane protein PorA (P1.16), its human IgG subclass derivatives (hIgG1 to hIgG4), and an mIgG2a monoclonal antibody (Nmb735) to serogroup B capsular polysaccharide (B-PS) were evaluated for passive protection against meningococcal serogroup B strain 44/76-SL (B:15:P1.7,16) in an infant rat infection model. Complement component C6-deficient (PVG/c–) rats were used to assess the importance of complement-mediated bacterial lysis for protection. The PorA-specific parental mIgG2a and the hIgG1 to hIgG3 derivatives all induced efficient bactericidal activity in vitro in the presence of human or infant rat complement and augmented bacterial clearance in complement-sufficient HsdBrlHan:WIST rats, while the hIgG4 was unable to do so. In C6-deficient PVG/c– rats, lacking complement-mediated bacterial lysis, the augmentation of bacterial clearance by PorA-specific mIgG2a and hIgG1 antibodies was impaired compared to that in the syngeneic complement-sufficient PVG/c+ rat strain. This was in contrast to the case for B-PS-specific mIgG2a, which conferred similar protective activity in both rat strains. These data suggest that while anti-B-PS antibody can provide protection in the infant rats without membrane attack complex formation, the protection afforded by anti-PorA antibody is more dependent on the activation of the whole complement pathway and subsequent bacterial lysis.

* Corresponding author. Mailing address: National Public Health Institute, Department of Vaccines, Vaccine Immunology Laboratory, Mannerheimintie 166, FIN-00300 Helsinki, Finland. Phone: 358-9-47448873. Fax: 358-9-47448599. E-mail: maija.toropainen{at}ktl.fi.

Editor: J. N. Weiser

Infection and Immunity, May 2006, p. 2803-2808, Vol. 74, No. 5
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.5.2803-2808.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gorringe, A. R., Taylor, S., Brookes, C., Matheson, M., Finney, M., Kerr, M., Hudson, M., Findlow, J., Borrow, R., Andrews, N., Kafatos, G., Evans, C. M., Read, R. C. (2009). Phase I Safety and Immunogenicity Study of a Candidate Meningococcal Disease Vaccine Based on Neisseria lactamica Outer Membrane Vesicles. CVI 16: 1113-1120 [Abstract] [Full Text]  
  • Plested, J. S., Welsch, J. A., Granoff, D. M. (2009). Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity. CVI 16: 785-791 [Abstract] [Full Text]  
  • Granoff, D. M., Welsch, J. A., Ram, S. (2009). Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera. Infect. Immun. 77: 764-769 [Abstract] [Full Text]  
  • Sandbu, S., Feiring, B., Oster, P., Helland, O. S., Bakke, H. S. W., Naess, L. M., Aase, A., Aaberge, I. S., Kristoffersen, A.-C., Rydland, K. M., Tilman, S., Nokleby, H., Rosenqvist, E. (2007). Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines. CVI 14: 1062-1069 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»